
pmid: 6336840
Captopril (Capoten) and minoxidil (Loniten) have recently become generally available for treatment of hypertension, and calcium channel blockers, although not yet officially approved for this indication, clearly have potential as antihypertensive agents. Captopril, the only available inhibitor of angiotensin-converting enzyme, is particularly effective in patients with severe, high-renin hypertension. Minoxidil, a potent direct-acting vasodilator, is particularly effective in severely hypertensive patients with concomitant renal insufficiency. Because serious side effects have been noted with both drugs, their use probably should not be considered until other agents have failed. Of the calcium channel blockers, nifedipine (Procardia) seems to have greatest promise as an antihypertensive agent.
Captopril, Pyrimidines, Proline, Hypertension, Minoxidil, Humans, Calcium Channel Blockers
Captopril, Pyrimidines, Proline, Hypertension, Minoxidil, Humans, Calcium Channel Blockers
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 4 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
